1. Background {#sec1}
=============

1.1. Myocardial Infarction: Disease Burden and Therapeutic Options {#sec1.1}
------------------------------------------------------------------

Incoronary artery disease, a critical reduction of the blood supply to the heart may result in myocardial infarction (MI), a phenomenon owing to the formation of an area of necrosis in heart muscles caused by inadequate supply of blood to the muscles, usually as a result of occlusion of a coronary artery. About a quarter of MI patients will die from it due to complications including cardiogenic shock, cardiac perforation, embolism, heart failure, papillary muscle rapture, rhythm disturbances, or autoimmune pericarditis. Current evidence on biomedicine (BM) treatment suggests that aspirin, thrombolytics with or without adding low-molecular-weight heparin, beta-blockers, ACE inhibitors, and nitrates are beneficial for improving outcomes in people with MI. Invasive procedures including coronary artery bypass grafting (CABG) and percutaneous transluminal coronary angioplasty (PTCA, balloon angioplasty) were also found to be useful. However, their efficacy in preventing death is not without limitations. For instance, beta-blockers have no short-term effect on mortality, and they may increase the risk of cardiogenic shock. Thrombolytics may cause stroke and major bleeding while reducing mortality, and those who are treated will receive no additional benefits from nitrates \[[@B1]\].

Despite these therapeutic advances, coronary artery disease remained to be the foremost leading cause of death in both low- and middle income countries as well as high-income countries, contributed 11.8% and 17.3% of total deaths, respectively \[[@B2]\]. Researchers are evaluating the potential benefits and harms of add-on treatments like vasodilators and positive inotropes on mortality \[[@B3]\]. Chinese herbal medicine (CHM) is another novel candidate as an add-on treatment.

1.2. Chinese Herbal Medicine for Treating Myocardial Infarction {#sec1.2}
---------------------------------------------------------------

In China, CHM is widely prescribed in both outpatient and inpatient settings \[[@B4]\]. Amongst community health clinics, 75% provide both BM and traditional Chinese medicine (TCM) treatments. TCM hospitals comprised 13.8% of all hospitals, and 90% of the BM hospitals are annexed with TCM departments \[[@B5]\]. Given the omnipresence of TCM services within the Chinese healthcare system, it is not uncommon for clinicians to prescribe CHM as an adjunct to BM treatment in the management of potentially life-threatening conditions including MI \[[@B6]\]. One of the most researched single herbs is *Radix Astragali,*which exerts its therapeutic effectiveness by inhibiting cardiac fibrosis, reducing infarct size, and increasing capillary and arteriole densities \[[@B7]\]. Commonly used Chinese proprietary medicines include Shexiangbaoxin tablets and Tongxinluo capsules. Shexiangbaoxin tablets are found to slow MI pathogenesis by inhibiting hypertrophy related metabolites \[[@B8]\]. On the other hand, Tongxinluo capsules act by promoting local blood supply and thus limit infarct size \[[@B9]\]. CHM injections based on sheng mai san are also widely prescribed. It reduces infarct size via the activation of protein kinase C, opening of the mitochondrial KATP channels, and lowering the concentration of 5-hydroxytryptamine, norepinephrine, methionine-enkephalin, and leucine-enkephalin \[[@B10], [@B11]\].

1.3. Synthesizing Chinese Herbal Medicine Trials: Focusing on Objective Outcomes {#sec1.3}
--------------------------------------------------------------------------------

The average effect of these CHM formulae as an adjunct to BM could be estimated using random effect meta-analyses of randomized controlled trials (RCTs) \[[@B12]\]. One of the major caveats in conducting systematic reviews on CHM is that existing RCTs are often prone to high risks of bias, thus limiting their usefulness in elucidating treatment effectiveness \[[@B13]\]. However, results from a recent metaepidemiological study have provided an alternative perspective on this issue. It is suggested that objective outcomes are less susceptible to bias associated with inadequate allocation concealment and blinding \[[@B14], [@B15]\]. Accordingly, by focusing on objective outcomes like mortality, we may partially overcome limitations imposed by the relatively high risk of bias amongst CHM trials.

1.4. Aim of This Paper {#sec1.4}
----------------------

Taking into account the methodological considerations above, we performed a systematic review and meta-analysis of RCTs on the efficacy and safety of CHM for MI as an add-on to BM treatment, with a focus on objective critical outcomes including death, recurrent myocardial infarction, and other post-MI cardiac consequences.

2. Methods {#sec2}
==========

2.1. Criteria for Considering Studies for This Paper {#sec2.1}
----------------------------------------------------

We included RCTs comparing the efficacy and safety of CHM plus BM versus BM alone. CHM is defined as any preparation containing at least one herb or its extraction referenced in the 2010 Chinese Pharmacopeia \[[@B16]\]. We included RCTs which enrolled adult MI patients regardless of gender, age, ethnicity, or comorbidities. We focused on the primary outcomes of (i) mortality of cardiac origin and (ii) all-cause morality. We also consider the following as secondary outcomes: (i) recurrence of MI and (ii) other nonfatal, post-MI cardiac outcomes including cardiac arrhythmia, heart failure, cardiac rupture, cardiogenic shock, and angina. Adverse events reported by authors were also summarized. We imposed no restrictions on language and publication status.

2.2. Search Methods for Identification of Studies {#sec2.2}
-------------------------------------------------

We searched 8 electronic databases since their inception to July 2010, including CENTRAL, MEDLINE, EMBASE, CINAHL, AMED, Chinese Biomedical Database (CBM), Chinese Medical Current Contents (CMCC), and Traditional Chinese Medical Literature Analysis and Retrieval System (TCMLARS) ([Figure 1](#fig1){ref-type="fig"}). Search strategies are shown in Appendix 1 in the Supplementary Materials available online at http://dx.doi.org/10.1155/2013/675906.

2.3. Data Collection and Analysis {#sec2.3}
---------------------------------

### 2.3.1. Selection of Studies, Data Extraction, and Risk of Bias Assessment {#sec2.3.1}

Two reviewers (Y. Qin and C. Mao) independently screened the titles and abstracts to assess their eligibility. Full texts of potentially eligible citations were retrieved for detailed examination. Selection discrepancies were settled through discussions between these two authors. The remaining disagreements were resolved by consulting another author (J. L. Tang). For included RCTs, comprehensive information on patients, CHM interventions, and baseline and control treatments, as well as outcomes, was extracted. Risks of bias amongst included RCTs were evaluated by the Cochrane collaboration\'s risk of bias assessment tool \[[@B17]\]. The assessment composed of a description and a judgement for each entry in a risk of bias table, including (i) sequence generation, (ii) allocation sequence concealment, (iii) incomplete outcome data, (iv) selective outcome reporting, and (v) other potential sources of bias. Blinding was assessed for the primary outcome of all-cause morality.

### 2.3.2. Data Analysis {#sec2.3.2}

Analyses were conducted using Stata 11 and R software. Dichotomous efficacy outcomes were expressed as relative risk reduction (RRR) and relative risk (RR), while RR was used for adverse events. 95% confidence intervals (CIs) were calculated for all estimates. We performed random-effect meta-analysis separately for each outcome. For primary outcomes of all-cause mortality and cardiac death, funnel plots were drawn for assessing publication bias. In case of asymmetry, random trim and fill analysis were performed as a sensitivity analysis \[[@B18]\]. Tests for heterogeneity were performed with chi-squared testes, at a significance level of *P* = 0.1. *I* ^2^ statistic was calculated to estimate variation across studies. We regarded *I* ^2^ \< 25% as an indicator of low heterogeneity level, 25--50% as moderate level, and higher than 50% as high level \[[@B19]\]. Heterogeneity was explored with random-effect metaregression using baseline risk, mean age, route of drug administration (oral versus intravenous), and treatment duration as covariates, taking into account the sample size requirement of including not more than 1 covariate for every 10 studies \[[@B20]\]. We expected that higher baseline risk and mean age could be associated with a smaller effect \[[@B1]\], while intravenous administration and longer treatment duration could be associated with a larger effect.

3. Results {#sec3}
==========

3.1. Literature Search {#sec3.1}
----------------------

As shown in [Figure 1](#fig1){ref-type="fig"}, our search in electronic bibliographical databases yielded 12,666 citations after removal of duplications, of which 2,660 were classified as potentially relevant and were subjected to a full-text assessment. A total of 65 RCTs published in 63 articles met the inclusion criteria. Details of these studies are presented in [Table 1](#tab1){ref-type="table"}.

3.2. Study Characteristics {#sec3.2}
--------------------------

A total of 6,036 patients were enrolled in the CHM plus BM group, and 5,986 patients were allocated to the BM only group. The average size of the trials was 185 participants (ranging from 28 to 2735 participants per trial). Fifty trials reported treatment duration and the average duration was 68.9 days, ranging from 3 to 1440 days. Forty-nine trials reported the length of followup. The average follow-up length was 7.1 months, ranging from 0.1 to 84 months.

For diagnostic criteria, 36 (55.4%) studies applied the 1979 World Health Organization criteria, which enrolled patients with at least two of the following three presentations: chest pain or discomfort, an elevation in CK-MB levels, or an ECG with significant ST-segment elevations \[[@B84]\]. Four adopted criteria from the Chinese Society of Cardiology \[[@B85]\] and one used criteria from the European Society of Cardiology \[[@B86]\]. Twelve applied author-defined diagnostic criteria, and the remaining 12 did not report criteria used.

Thirty-one standardized Chinese herbal formulae were examined in 63 (96.9%) of the 65 included studies, while the other two studies used an individualized approach. 32 (50.0%) preparations were administrated orally, 30 (46.9%) were prescribed as herbal injections, and 2 (3.12%) trials used both intravenous and oral treatments. Eight formulae were evaluated by three or more trials. In total, these formulae were assessed in 38 studies, constituting 58.5% of all included trials. Nine (13.8%) trials studied Shenmai injection, which contains ginsenoside, ginseng polysaccharide, Ophiopogon polysaccharides, and Ophiopogon flavonoids extracted from*Panax ginseng*and *Ophiopogon japonicas*.Five (7.7%) evaluated Huangqi injection manufactured by extracting astragalosides from*Radix Astragali*.Another five (7.7%) assessed Shexiangbaoxin tablets, which consisted of Moschus, *Radix Ginseng*, *Borneolum Syntheticum*, *Venenum Bufonis*, *Cortex Cinnamomi*, *Calculus Bovis*, and Styrax.Four (6.2%) tested Shengmai injection, which is a mixture of extracts from*Panax ginseng*, *Radix Ophiopogonis*, and *Schisandra chinensis Baill.*Another four (6.2%) evaluated Tongxinluo capsules, consisting of *Radix Ginseng,*Scorpio*, Hirudo,* Eupolyphaga *seu Steleophaga, Scolopendra, Periostracum Cicadae, Radix Paeoniae Rubra,*and*Borneolum Syntheticum.*Three trials (4.6%) assessed Shenfu injection, which contains Ginsenoside and Aconitine extracted from *Panax ginseng and Aconitum carmichaelii.*Another three evaluated Suxiao jiuxin pill (4.6%), consisting of*Ligusticum chuanxiong*Hort. And *Borneolum syntheticum.*Finally, three (4.6%) studies tested Xuezhikang capsule, which comprise partially purified extract of fermented *Monascus purpureus.*

3.3. Risk of Bias {#sec3.3}
-----------------

Among these 65 RCTs, only 7 were at low risk for bias for allocation sequence generation. Twelve were at high risk and the remaining RCTs did not report their sequence generation procedure clearly. All but one had high risk of bias in terms of allocation concealment and none of the included studies report the use of blinding. However, we regarded the risks of bias associated with lack of blinding and allocation concealment to be minimal, as the primary outcomes were of objective nature. Two of the included studies had high risk of bias for incomplete data and one for selective outcome reporting. Six are at high risk of bias due to other reasons. In summary, we consider the overall risk of bias amongst our included studies to be moderate ([Figure 2](#fig2){ref-type="fig"}). The detailed risk of bias assessment results is presented in Appendix 2 in the supplementary materials.

3.4. Effects of Interventions {#sec3.4}
-----------------------------

### 3.4.1. Impact on Fatal Outcomes {#sec3.4.1}

In this comparison ([Table 2](#tab2){ref-type="table"}), a total of 44 RCTs reported total all-cause mortality. Pooled results demonstrated superiority of combined treatment in preventing all-cause mortality (RRR = 37%, 95% CI = 28%--45%). Funnel plot indicates the presence of publication bias. After applying trim and fill procedure ([Figure 3](#fig3){ref-type="fig"}), the RRR remained to be significant (RRR = 29%, 95% CI = 16%--40%, [Table 2](#tab2){ref-type="table"}). Ten RCTs reported death of cardiac origin, and pooled findings also favor combined treatment (RRR = 39%, 95% CI = 22%--52%). Funnel plot indicates the presence of publication bias. After applying trim and fill procedure, the RRR remained to be significant (RRR = 32%, 95% CI = 15%--46%).

Pooled results from another four RCTs reporting the occurrence of fatal cardiogenic shock also favored combined treatment (RRR = 28%, 95% CI = 5%--45%). Respectively nine, six, five, and three RCTs reported outcomes on sudden cardiac death, fatal myocardial reinfarction, fatal heart failure, and fatal cardiac arrhythmia. In these four comparisons, all pooled findings favored combined treatment (sudden cardiac death: RRR = 24%, 95% CI = 6%--45%; fatal cardiac reinfarction: RRR = 54%, 95% CI = 12%--81%; fatal heart failure: RRR = 52%, 95% CI = 9%--79%; fatal cardiac arrhythmia: RRR = 29%, 95% CI = 84%--222%), but the estimates were statistically insignificant. Except for fatal myocardial reinfarction (*I* ^2^ = 37.3%), no significant heterogeneity existed in the comparisons mentioned above. However, given the small number of RCTs reporting this outcome, we were unable to explore heterogeneity using metaregression.

### 3.4.2. Impact on Nonfatal Cardiovascular Events {#sec3.4.2}

In this comparison ([Table 2](#tab2){ref-type="table"}), a total of 11 RCTs reported overall, undifferentiated nonfatal heart events. Pooled results demonstrated superiority of combined treatment in preventing this outcome (RRR = 48%, 95% CI = 40%--56%). Twenty-three RCTs evaluated myocardial reinfarction, and the pooled result favors combined treatment (RRR = 52%, 95% CI = 39%--61%). The pooled results from 14 and 24 RCTs have also favored combined treatment, respectively, in preventing cardiogenic shock (RRR = 37%, 95% CI = 15%--53%) and in alleviating angina symptoms (RRR = 53%, 95% CI = 46%--61%). Three RCTs investigated nonfatal cardiac rupture as an outcome.The pooled finding supports combined treatment but the estimate was statistically insignificant (RRR = 56%, 95% CI = 67%--89%). No significant heterogeneity existed in all meta-analyses mentioned above.

Respectively, thirty and twenty-eight RCTs reported outcomes of cardiac arrhythmia and heart failure. In these two groups of studies, pooled findings all favored combined treatment, but high level of heterogeneity existed in both estimates (cardiac arrhythmia: RRR = 41%, 95% CI = 27%--52%, *I* ^2^ = 76.2%; heart failure: RRR = 48%, 95% CI = 36%--58%, *I* ^2^ = 47.9%).

### 3.4.3. Metaregression {#sec3.4.3}

We explored these heterogeneities by performing multivariate metaregression analyses using mean age, treatment duration, route of administration (oral versus intravenous), and baseline risk as covariates. None of the four covariates is significantly associated with cardiac arrhythmia (for baseline risk regression coefficient (*β*) = 0.46, *P* = 0.41; for mean age *β* = 0.00, *P* = 0.96; for duration of treatment *β* = 0.00, *P* = 0.95; for route of administration *β* = 0.21, *P* = 0.63), or heart failure (for baseline risk *β* = 0.67, *P* = 0.39; for mean age *β* = 0.02, *P* = 0.57; for duration of treatment *β* = 0.00, *P* = 0.87; for route of administration *β* = 0.12, *P* = 0.77).

### 3.4.4. CHM and BM versus BM Alone for MI: Adverse Events {#sec3.4.4}

In this comparison ([Table 2](#tab2){ref-type="table"}), nine RCTs reported bleeding as adverse events, but the pooled estimate was statistically insignificant (RR = 0.97, 95% CI = 0.73, 1.28). Two RCTs reported general, undifferentiated adverse events, pooled estimate is heterogeneous and statistically insignificant (RR = 1.16, 95% CI = 0.59, 2.27, *I* ^2^ = 54.4%).

4. Discussion {#sec4}
=============

This systematic review on the add-on effect of CHM on BM in the treatment of MI summarized findings from 12,022 patients reported in 65 RCTs. The overall risk of bias amongst included studies was moderate. Despite the lack of allocation concealment and blinding in the majority of included trials, its impact on risk of bias was less critical as we focused on objective outcomes. Random-effect meta-analyses demonstrated that combined treatment is superior to BM alone in reducing the risk of all-cause mortality and death of cardiac origin. Funnel plots indicated the presence of publication bias for both outcomes, and trim and fill procedures were conducted as sensitivity analyses. The directions of effect did not change after the adjustment, and the 95% CI of the estimates overlapped with the unadjusted values. The lower 95% CI boundary of the trim- and fill-adjusted RRR for all-cause and cardiac mortality was 16% and 15%, respectively. Conservatively speaking, CHM appeared to offer a protective add-on effect against mortality after adjusting for the publication bias, a common problem amongst the clinical research literature on CHM \[[@B87]\].

Combined treatment is also found to be more effective than BM alone in lowering the risk of fatal cardiogenic shock. Our analyses did not demonstrate therapeutic benefits of combined treatment on other reviewed fatal outcomes including myocardial reinfarction, cardiac arrhythmia, heart failure, and sudden cardiac death. For nonfatal outcomes, our analyses demonstrated that CHM is an effective add-on for lowering the risk of cardiogenic shock, cardiac arrhythmia, myocardial reinfarction, and the occurrence of total heart events. Benefits in preventing heart failure and angina were also observed but these findings are less robust given the subjective nature of the outcome, and metaregression did not shed light on potential sources of heterogeneity. We have considered including allocation concealment and blinding as covariates in our metaregressions but numbers of trials with low risk in these domains are too small for conducting such analysis. The effect of combined treatment on these two outcomes would need to be further evaluated with methodologically stronger trials. In addition, more comprehensive reporting on BM treatment details and adverse events is expected in future studies, preferably with reference to the CONSORT statement.

Comprehensiveness of search is the major strength of this systematic review. The use of both international and Chinese databases allowed us to locate a much higher number studies compared to seven existing reviews on the topic \[[@B88]\]. We also attempted to synthesize results from trials evaluating heterogeneous CHM using random-effect model. This allowed us to estimate the average effect of adding CHM on top of conventional therapies \[[@B12]\]. The use of the trim and fill method has also partly circumvented the problem of publication bias. Nevertheless, the robustness of our conclusion depends on the assumption that the objective nature of outcomes was less affected by two major sources of bias: allocation concealment and blinding. While this assumption is tested in metaepidemiological studies \[[@B89], [@B90]\], the generalizability of these findings warrants further investigations.

5. Conclusion {#sec5}
=============

Based on RCTs of moderate quality, this systematic review demonstrated consistent, add-on benefits of using CHM on top in BM treatment for preventing all-cause and cardiac mortality amongst MI patients. These findings are in line with the results from seven existing systematic reviews of smaller scope and lower methodological quality. This tentative conclusion warrants further scrutiny using rigorously designed RCT, and a more comprehensive approach in reporting BM treatment details and adverse events is warranted.

Supplementary Material {#supplementary-material-sec}
======================
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###### 

Main characteristic of included studies.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author             Year   No. of patients in the treatment group   No. of patients in the control group   Diagnostic criteria                                 Intervention                                                                                      Control                       Duration of treatment (days)   Duration of followup (months)
  ------------------------ ------ ---------------------------------------- -------------------------------------- --------------------------------------------------- ------------------------------------------------------------------------------------------------- ----------------------------- ------------------------------ -------------------------------
  CHD Group \[[@B21]\]     1981   138                                      138                                    Not reported                                        Kangxingeng heji + BM                                                                             BM                            N/A                            N/A

  Kou \[[@B22]\]\          1983   133                                      135                                    WHO criteria                                        Yiqihuoxue decoction and In + Xuejie powder + BM                                                  BM                            N/A                            N/A

  Chen \[[@B23]\]          1984   112                                      112                                    WHO criteria                                        Yiqihuoxue decoction + Yiqihuoxue In + BM                                                         BM                            35                             N/A

  Liang \[[@B24]\]         1989   74                                       74                                     Author defined                                      Tuoqingyanhu su + BM                                                                              BM                            N/A                            N/A

  Xia \[[@B25]\]           1993   23                                       10                                     Not reported                                        Dushen tang + thrombolysis                                                                        Thrombolysis                  3                              N/A

  Li \[[@B26]\]            1994   60                                       64                                     WHO criteria                                        Wenyanghuoxue decoction + BM                                                                      BM                            14                             0.1

  Li \[[@B27]\]            1994   18                                       15                                     WHO criteria                                        Huangqi In + polarized solution                                                                   BM + polarized solution       28                             1

  Yang \[[@B28]\]          1997   66                                       80                                     WHO criteria                                        Shexiangbaoxin tablets + BM                                                                       BM                            360                            12

  Zhang \[[@B29]\]         1998   76                                       59                                     WHO criteria                                        JianXin tablet + BM                                                                               BM                            30                             1

  Guo \[[@B30]\]           1999   243                                      259                                    WHO criteria                                        Shenmai In + thrombolysis                                                                         Thrombolysis                  14                             1.25

  Li \[[@B31]\]            1999   51                                       50                                     WHO criteria                                        Ligustrazine + compound danshen In + Chinese medicinal formulae + thrombolysis                    Thrombolysis                  28                             1

  Zhang \[[@B32]\]         1999   52                                       47                                     WHO criteria                                        Yiqihuoxuetongluo decoction + BM                                                                  BM                            28                             1

  Guo \[[@B33]\]           2000   143                                      159                                    WHO criteria                                        Suxiao jiuxin pills + thrombolysis                                                                Thrombolysis                  14                             1.25

  Han \[[@B34]\]           2000   38                                       44                                     WHO criteria                                        Huangqi In + thrombolysis                                                                         Thrombolysis                  10                             1

  Li \[[@B35]\]            2000   28                                       19                                     WHO criteria                                        Zhupi decoction + BM                                                                              BM                            7                              0.25

  Li QZ (a) \[[@B36]\]\*   2000   66                                       80                                     WHO criteria                                        Suxiao jiuxin pills + BM                                                                          BM                            360                            12

  Li QZ (b) \[[@B36]\]\*   2000   66                                       72                                     WHO criteria                                        Suxiao jiuxin pills + BM                                                                          BM + Propranolol              360                            12

  Lu \[[@B37]\]            2000   21                                       21                                     WHO criteria                                        Shuizhi In + BM                                                                                   BM                            14                             0.5

  Yin \[[@B38]\]           2000   15                                       13                                     WHO criteria                                        Shenmai In + Herba Erigerontis In + BM + thrombolysis                                             BM + Thrombolysis             14                             N/A

  Wu \[[@B39]\]            2001   54                                       49                                     WHO criteria                                        Huangqi In + Dan-Shen In + BM                                                                     BM                            14                             0.75

  Bai \[[@B40]\]           2002   62                                       60                                     WHO criteria                                        Shenmai In + BM                                                                                   BM                            14                             N/A

  Shi \[[@B41]\]           2002   58                                       56                                     Author defined                                      Breviscapinun + BM + thrombolysis                                                                 BM + Thrombolysis             20                             0.67

  Guan \[[@B42]\]          2003   30                                       30                                     WHO criteria                                        Xingding In + BM                                                                                  BM                            15                             1

  Zhang \[[@B43]\]         2003   45                                       45                                     Not reported                                        Shenfu decoction+Xuefuzhupi decoction + BM                                                        BM                            28                             N/A

  Han \[[@B44]\]           2004   46                                       52                                     WHO criteria                                        Shexiangbaoxin tablets + BM + thrombolysis                                                        BM + Thrombolysis             28                             1

  Li \[[@B45]\]            2004   32                                       18                                     WHO criteria                                        Shexiangbaoxin tablets + BM + thrombolysis                                                        BM + Thrombolysis + placebo   90                             3

  Liu \[[@B46]\]           2004   41                                       96                                     WHO criteria                                        Shenmai In + BM                                                                                   BM                            15                             N/A

  Yang \[[@B47]\]          2004   45                                       45                                     Not reported                                        Huangqi In + thrombolysis                                                                         Thrombolysis                  7                              6

  Chen \[[@B48]\]          2005   35                                       34                                     Not reported                                        Huangqi In + thrombolysis                                                                         Thrombolysis                  10                             12

  Deng \[[@B49]\]          2005   38                                       35                                     Not reported                                        Xingnaojing In + BM                                                                               BM                            21                             24

  He \[[@B50]\]            2005   23                                       23                                     Author defined                                      Kaixin capsule + BM + thrombolysis                                                                BM + thrombolysis             5                              0.17

  Li \[[@B51]\]            2005   83                                       83                                     Not reported                                        Diaohuangqi In + BM                                                                               BM                            28                             2

  Liu \[[@B52]\]\*         2005   30                                       22                                     WHO criteria                                        Treatment based on TCM syndrome differentiation + thrombolysis                                    Thrombolysis                  28                             1

  Miao \[[@B53]\]          2005   64                                       62                                     WHO criteria                                        Shengmai In + BM + thrombolysis                                                                   BM + thrombolysis             15                             2

  Yang \[[@B54]\]          2005   45                                       45                                     Criteria from the Chinese Society of Cardiology     Shexiangboxin tablets + BM                                                                        BM                            N/A                            3

  Ding \[[@B55]\]          2006   15                                       15                                     WHO criteria                                        Shengmai In + BM                                                                                  BM                            N/A                            N/A

  Du (a)\[[@B56]\]\*       2006   1364                                     1371                                   Not reported                                        Xuezhikang capsules + BM                                                                          BM + placebo                  N/A                            84

  Du (b) \[[@B56]\]\*      2006   1070                                     1065                                   Not reported                                        Xuezhikang capsules + BM                                                                          BM + placebo                  1440                           48

  Li \[[@B57]\]            2006   31                                       32                                     Guideline from the European Society of Cardiology   Shenfu In + BM                                                                                    BM                            14                             N/A

  Ma \[[@B58]\]            2006   25                                       25                                     Criteria from the Chinese Society of Cardiology     Yuxingeng decoction + BM                                                                          BM                            28                             1

  Qi \[[@B59]\]            2006   48                                       46                                     WHO criteria                                        Tanshinone II A sulfoacid In + BM + thrombolysis + PCI                                            BM + thrombolysis + PCI       14                             0.5

  Shen \[[@B60]\]          2006   83                                       82                                     Author defined                                      Shenfu In + BM                                                                                    BM                            N/A                            0.25

  Wang \[[@B61]\]          2006   228                                      162                                    WHO criteria                                        Shenmai In + BM                                                                                   BM                            14                             1

  Wei \[[@B62]\]           2006   31                                       37                                     WHO criteria                                        Shenfu In + BM + thrombolysis                                                                     BM + thrombolysis             7                              0.25

  Wu \[[@B63]\]            2006   19                                       21                                     WHO criteria                                        Shenmai In + BM                                                                                   BM                            20                             1

  Yang \[[@B64]\]          2006   48                                       49                                     Not reported                                        Xuezhikang capsules + BM                                                                          BM + placebo                  N/A                            72

  Chen \[[@B65]\]          2007   30                                       30                                     WHO criteria                                        Tongxinluo capsule + BM                                                                           BM                            56                             2

  Li \[[@B66]\]            2007   45                                       45                                     Author defined                                      Guanxinning In + BM                                                                               BM                            15                             6

  Liang \[[@B67]\]         2007   90                                       68                                     WHO criteria                                        Shengmai In or Shenmai In + treatment based on TCM syndrome Differentiation + BM + thrombolysis   BM                            N/A                            N/A

  Pan \[[@B68]\]           2007   20                                       20                                     WHO criteria                                        Tongxinluo capsule + BM                                                                           BM                            N/A                            1

  Zhai \[[@B69]\]          2007   38                                       30                                     Criteria from Chinese Society of Cardiology         Shenmai In + BM                                                                                   BM                            10                             N/A

  Ding \[[@B70]\]          2008   23                                       23                                     Author defined                                      Shengmai In + BM                                                                                  BM                            N/A                            N/A

  Lan \[[@B71]\]           2008   130                                      128                                    WHO criteria                                        Xinmaitong capsules + BM                                                                          BM                            30                             1

  Yu \[[@B72]\]            2008   100                                      96                                     Author defined                                      Shexiang Baoxin tablets + BM                                                                      BM                            10                             1

  Yu \[[@B73]\]            2008   32                                       32                                     Author defined                                      Yinxingdamo In + BM + thrombolysis                                                                BM + thrombolysis             14                             0.5

  Zhang \[[@B74]\]         2008   27                                       27                                     WHO criteria                                        Shenmai In + Shuxuening In + BM                                                                   BM                            28                             N/A

  Gao \[[@B75]\]           2009   60                                       60                                     WHO criteria                                        Danhong In + BM                                                                                   BM                            N/A                            0.5

  Lin \[[@B76]\]           2009   25                                       25                                     Author defined                                      Compound danshen dripping pills + BM                                                              BM                            N/A                            1

  Liu \[[@B77]\]           2009   16                                       16                                     Author defined                                      Tanshinone II A sulfoacid In + BM                                                                 BM                            7                              3

  Song \[[@B78]\]          2009   36                                       34                                     Author defined                                      Tongxinluo capsule + Shenmai In + Gegensu In + BM                                                 BM                            28                             N/A

  Yuan \[[@B79]\]          2009   38                                       38                                     WHO criteria                                        Shenmai In + thrombolysis                                                                         Thrombolysis                  10                             1

  Zhao \[[@B80]\]          2009   50                                       48                                     Not reported                                        Tongxinluo capsule + BM + thrombolysis                                                            BM + thrombolysis             N/A                            12

  Zuo \[[@B81]\]           2009   80                                       80                                     Criteria from Chinese Society of Cardiology         Breviscapinun + BM                                                                                BM                            14                             1

  Guo \[[@B82]\]           2010   48                                       45                                     Not reported                                        Compound Danshen tablet + BM                                                                      BM                            N/A                            12

  Xu \[[@B83]\]            2010   32                                       30                                     Author defined                                      Treatment based on TCM syndrome differentiation + BM                                              BM                            28                             1
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BM: routine biomedical treatment as defined by the investigators; In: injection; N/A: not reported.

\*Two RCTs reported in one publication.

###### 

Chinese herbal medicine plus biomedical treatment versus biomedical treatment alone for treating myocardial infarction: random-effect meta-analysis.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Events                                 No. of studies   No. of events/total no.   Combined effect   Test for heterogeneity   Adjusted combined effect (trim and fill)                                                                  
  -------------------------------------- ---------------- ------------------------- ----------------- ------------------------ ------------------------------------------ --------- -------- ------- ------ -------------- ------------- ---------
  Fatal events                                                                                                                                                                                                                            

   All-cause mortality                   44               308/5107                  521/5112          0.63\                    37%\                                       \<0.001   37.47    0.709   0.0    0.71\          29%\          \<0.001
                                                                                                      (0.55--0.72)             (28%--45%)                                                                   (0.60--0.84)   (16%--40%)    

   Mortality of cardiac origin           10               142/2820                  227/2796          0.61\                    39% (22%--52%)                             \<0.001   11.66    0.233   22.8   0.68\          32%\          0.001
                                                                                                      (0.48--0.78)                                                                                          (0.54--0.85)   (15%--46%)    

   Fatal myocardial reinfarction         6                20/2660                   37/2687           0.46\                    54% (12%--81%)                             0.086     7.98     0.157   37.3   ---                          ---
                                                                                                      (0.19--1.12)                                                                                                                       

   Fatal cardiac arrhythmia              3                4/162                     5/160             0.71\                    29%\                                       0.662     2.21     0.331   9.6    ---                          ---
                                                                                                      (0.16--3.22)             (84%--222%)                                                                                               

   Fatal heart failure                   5                8/410                     18/444            0.48\                    52%\                                       0.078     0.06     1.000   0.0    ---                          ---
                                                                                                      (0.21--1.09)             (9%--79%)                                                                                                 

   Fatal cardiogenic shock               4                37/330                    58/332            0.72\                    28%\                                       0.019     2.42     0.490   0.0    ---                          ---
                                                                                                      (0.55--0.95)             (5%--45%)                                                                                                 

   Sudden cardiac death                  9                61/2775                   81/2795           0.76\                    24%\                                       0.104     3.13     0.926   0.0    ---                          ---
                                                                                                      (0.55--1.06)\            (6%--45%)                                                                                                 

  Nonfatal events                                                                                                                                                                                                                         

   Undifferentiated total heart events   11               209/2762                  407/2761          0.52\                    48%\                                       \<0.001   8.99     0.533   0.0    0.52\          48%\          \<0.001
                                                                                                      (0.44--0.60)             (40%--56%)                                                                   (0.44--0.62)   (38%--56%)    

   Myocardial reinfarction               23               103/2377                  215/2343          0.48\                    52% (39%--61%)                             \<0.001   9.95     0.987   0.0    0.53\          47%\          \<0.001
                                                                                                      (0.39--0.61)                                                                                          (0.43--0.66)   (34%--57%)    

   Cardiac arrhythmia                    30               398/1730                  640/1696          0.59\                    41% (27%--52%)                             \<0.001   121.94   0.000   76.2   0.72\          28%\          0.003
                                                                                                      (0.48--0.73)                                                                                          (0.58--0.89)   (11%--42%)    

   Heart failure                         28               249/1825                  496/1835          0.52\                    48%\                                       \<0.001   51.86    0.003   47.9   0.60\          40%\          \<0.001
                                                                                                      (0.42--0.64)             (36%--58%)                                                                   (0.50--0.72)   (28%--50%)\   

   Cardiac rupture                       3                2/122                     7/134             0.44\                    56%\                                       0.224     0.60     0.740   0.0    ---                          ---
                                                                                                      (0.11--1.67)             (67%--89%)                                                                                                

   Cardiogenic shock                     14               63/1015                   110/1030          0.63\                    37%\                                       0.002     10.65    0.640   0.0    0.75\          25%\          0.036
                                                                                                      (0.47--0.85)             (15%--53%)                                                                   (0.57--0.98)   (2%--43%)     

   Angina                                24               177/1047                  297/1001          0.47\                    53%\                                       \<0.001   22.20    0.508   0.0    0.58\          42%\          \<0.001
                                                                                                      (0.39--0.56)             (44%--61%)                                                                   (0.48--0.69)   (31%--52%)    

  Adverse events                                                                                                                                                                                                                          

   Undifferentiated total events         2                43/2434                   39/2436           1.16\                    16%\                                       0.664     2.19     0.138   54.4   ---                          ---
                                                                                                      (0.59--2.27)             (41%--127%)                                                                                               

   Bleeding                              9                81/706                    81/745            0.97\                    3%\                                        0.816     4.89     0.769   0.0    ---                          ---
                                                                                                      (0.73--1.28)             (27%-28%)                                                                                                 
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^\#^Test for overall effect; \*chi-square test for heterogeneity.

BM: biomedical treatment; CHM: Chinese herbal medicine treatment; RR: relative risk; RRR: relative risk reduction; 95% CI: 95% confidence interval.

[^1]: Academic Editor: Vassya Bankova
